RGEN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Repligen Corp (RGEN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown revenue growth, its declining net income and EPS, along with insider selling and no strong trading signals, suggest a cautious approach. The stock's technical indicators and options data do not present a compelling entry point for immediate investment.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 62.961, and moving averages are converging, suggesting no strong trend. The stock is trading near a resistance level (R1: 121.295) with support at 116.241, indicating limited upside potential in the short term.
Revenue increased by 18.12% YoY in Q4 2025, and gross margin improved by 9.45%. Analysts maintain positive ratings with some projecting upside potential.
Net income dropped significantly by -139.23% YoY, and EPS declined by -138.33%. Insider selling has increased by 143.49% over the last month. No recent news or event-driven catalysts.
In Q4 2025, revenue increased to $197.91M (up 18.12% YoY), but net income dropped to $13.29M (-139.23% YoY), and EPS fell to $0.23 (-138.33% YoY). Gross margin improved to 52.46% (up 9.45% YoY).
Analysts have lowered price targets recently, with the latest target at $140 from Evercore ISI. However, other firms like H.C. Wainwright and UBS maintain higher targets ($208 and $195, respectively) and positive ratings, citing strong growth drivers and potential upside.
